Exicure to Present at Upcoming Scientific Conferences
10/07/2021 - 07:00 AM
CHICAGO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--
Exicure , Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced presentations in the following scientific conferences during the month of October:
17th International Congress on Neuronal Ceroid Lipofuscinosis (NCLs)
Title: "Development of Spherical Nucleic Acids Targeting CLN3 for the Treatment of Batten Disease"
Presented by: Grant Corbett , Group Lead, Neuroscience
Date: Friday, October 8, 2021
Time: 4:50 - 5:05 PM CDT
International OligonucIeotides and Peptides Conference (IOPC) 2021
Title: “Spherical Nucleic Acids Facilitate Efficient Local Delivery Across Therapeutic Areas”
Presented by: Matthias Schroff , COO
Date: Monday, October 18, 2021
Time: 8:55 - 9:25 AM CDT
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN, a lipid-nanoparticle SNA–based therapeutic candidate, for the intrathecal treatment of Friedreich’s ataxia (FA). Exicure’s therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is based in Chicago, IL and in Cambridge, MA. www.exicuretx.com
View source version on businesswire.com : https://www.businesswire.com/news/home/20211007005139/en/
Karen Sharma
MacDougall
781-235-3060
ksharma@macbiocom.com
Source: Exicure, Inc.
XCUR Rankings
N/A Ranked by Stock Gains
XCUR Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Miscellaneous Commercial Services, Commercial Services
Country
US
City
Skokie
About XCUR
exicure, formerly aurasense therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. our 3-dimensional, spherical nucleic acid (sna™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. our lead programs address diseases from inflammatory disorders to oncology. sna constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. sna constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. moreover, snas can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.